VEGF 165 (AA 27-191) (Active) Protein

Produktnummer ABIN2667603

Recombinant VEGF 165-Protein exprimiert in Escherichia coli (E. coli).

Kurzübersicht für VEGF 165 (AA 27-191) (Active) Protein (ABIN2667603)

Target: VEGF 165

Protein-Typ: Recombinant

Biologische Aktivität: Active

Spezies: Human

Quelle: Escherichia coli (E. coli)

Applikation: Western Blotting (WB), Chromatin Immunoprecipitation (ChIP), Immunofluorescence (IF), Immunoprecipitation (IP)

Reinheit: >98 % , as determined by Coomassie stained SDS-PAGE and HPLC analysis.

Produktdetails

Proteineigenschaft: AA 27-191

Endotoxin-Niveau:

Less than 0.1 ng per μg of protein.

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Kommentare:

Biological activity: ED50 is between 1.0-8.0 ng/ml, corresponding to a specific activity of 1.25-10 x 105 units/mg as determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC).

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: For maximum results, quick spin vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/mL. Do not vortex. It is recommended to further dilute in a buffer, such as 5 % Trehalose, and store working aliquots at -20 °C to -80 °C.

Buffer: Lyophilized, carrier-free.

Handhabung: Avoid repeated freeze/thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: Unopened vial can be stored at -20°C or -70°C.

Antigendetails

Target: VEGF 165

Andere Bezeichnung: VEGF-165

Hintergrund: VEGF (known also as VEGFA) was initially identified in conditioned medium from bovine pituitary follicular cells. VEGFA belongs to the VEGF family, which has the following members: VEGF-A, VEGF-B, VEGF-C (VEGF-2), VEGF-D, and PlGF (placental growth factor). In addition, viral VEGF homologs (collectively called VEGF-E) and snake venom VEGFs, such as T.f. (Trimeresurus flavoviridis) and svVEGF (called VEGF-F), have been described. VEGFA is alternatively spliced to generate variants with different numbers of amino acids, such as VEGFA121, VEGFA145, VEGFA165, and VEGFA189. VEGFA165 is predominant and responsible for VEGFA biological potency. While VEGF121 is freely diffusible and does not bind to neuropilins (NRPs) or heparan sulphate (HS), VEGF165 and VEGF189 bind to both, resulting in retention on the cell surface or in the extracellular matrix. NRP1 lacks a typical kinase domain and acts as a co-receptor, and in response to VEGF165, NRP1 couples with VEGF-Rs to signal in endothelial cells. In addition, it has been suggested that bone marrow cells that are recruited to Ewing's tumors are differentiated into vascular smooth muscle cells, and VEGF165 is responsible for this differentiation. VEGFA is highly expressed in most of the solid tumors generated in breast, lung, renal, colorectal, and liver tissues. VEGFA has strong vascular permeability activity, and significantly contributes to the formation of ascites tumors. VEGFA can act as a direct proinflammatory mediator during the pathogenesis of rheumatoid arthritis (RA), and protect rheumatoid synoviocytes from apoptosis, which contributes to synovial hyperplasia. VEGFA is expressed in synovial macrophages and synovial fibroblasts in RA patients. Also, VEGFA is associated to age-related macular degeneration (AMD). AMD is due to neovascularization that originates from endothelial cells in the choroid that grow into neurosensory retina as choroidal neovascularization (CNV).

Molekulargewicht: The 165 amino acid recombinant protein has a predicted Molecular mass of 19 kDa. The predicted N-terminal amino acid is Ala. Recombinant human VEGF165 is a disulfide bond linked homodimer.